Compare SiTime Corporation (SITM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SiTime Corporation vs TG Therapeutics Inc — how do they compare? SiTime Corporation trades at $615 (market cap $19.42B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: SiTime Corporation is far larger — about 2.4× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SiTime Corporation for 18 Days and TG Therapeutics Inc for 16 Days on average.
| SITM | TGTX | |
|---|---|---|
Market Cap | $19.42B | $8.16B |
Volume | 360,307 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $901.60 | $59.06 |
52-Week Low | $252.76 | $26.94 |
Typical Hold Time | 18 Days | 16 Days |
Enterprise Value | $18.82B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SITM trades at $612.37, down 7.94% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with a 126.5% revenue surge to $157.43M and achieving its first GAAP profit. Analyst consensus is unanimously bullish with a $751.43 price target, citing AI-driven growth and market leadership in MEMS timing solutions.
The outlook is positive, driven by AI infrastructure demand and operational leverage, but risks include high valuation multiples, negative 2025 net income, and insider selling. The stock offers significant upside potential if growth continues, though execution and market volatility pose challenges.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
